About Apollo Endo
Apollo Endo is a Healthcare company based in Austin (United States) founded in 2005, and was acquired by Boston Scientific in November 2022. Therapeutic devices for obesity and GI disorders are developed. Apollo Endo has raised $80.36 million across 13 funding rounds from investors including Boston Scientific, UTMB Health and PTV Healthcare Capital. The company has 132 employees. Its chief executive, as recorded, is Chas McKhann. Apollo Endo offers products and services including Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and Orbera. Its focus areas include Life Sciences, Obesity, Medical Devices and Therapeutic Devices. Its legal entity is APOLLO ENDOSURGERY, INC. Its competitors include Allurion, USGI Medical and ReShape; 3 of its 3 listed competitors have raised funding.
Company details
Apollo Endo was founded in 2005 in Austin, United States, focusing on medical devices within the gastrointestinal sector. Therapeutic solutions for obesity and related disorders are developed, including the Orbera intragastric balloon for portion control and weight management. Additional products encompass the OverStitch Endoscopic Suturing System for advanced endoscopic procedures and the LAP-BAND adjustable gastric banding system. Operations emphasize endoscopic innovations to support clinical applications.
- Headquarters Austin, United States
- Employees 132
- Stage Acquired
- SectorsHealthcare
- Website apolloendo.com
- Social LinkedIn X Facebook Instagram
- Acquired by Boston Scientific (Nov 2022)
- Legal Name Apollo Endosurgery, Inc.
- Annual Revenue$76.86 M (USD)22as on Dec 31, 2022
- Net Profit-$39.84 M (USD)-61as on Dec 31, 2022
- EBITDA-$31.42 M (USD)-64as on Dec 31, 2022
- Total Equity Funding$80.36M (USD)
in 13 rounds
- Latest Funding Round$25M (USD), Post-IPO
Jul 2020
- InvestorsBoston Scientific
& 8 more
- Employee Count132
- Acquired byBoston Scientific
(Nov 2022)
Products & Services of Apollo Endo
Apollo Endo offers a comprehensive portfolio of products and services, including Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and Orbera.
Reduces stomach size endoscopically to facilitate weight loss.
Adjusts previous gastric bypass for effective weight management.
Occupies stomach space to suppress appetite and aid weight loss.
Funding Insights of Apollo Endo
Apollo Endo has successfully raised a total of $80.36M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $25 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80.36M
- Total Rounds 13
- Last Round Post-IPO — $25M
- Investors Count 8
Latest 10 of 13 funding rounds of Apollo Endo with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $25M | Post-IPO | – | – | – |
| Aug 2019 | $20M | Post-IPO | – | – | – |
| Feb 2015 | $50M | Debt – Conventional | – | – | |
| Dec 2013 | $60.73M | Post-IPO | – | – | – |
| Jun 2013 | $5.04M | Post-IPO | – | – | – |
| Feb 2012 | $52.7M | Series C | – | Remeditex, HIG BioHealth Partners | |
| Mar 2009 | $3M | Debt – Conventional | – | – | – |
| Mar 2008 | $12.71M | Series B | – | – | – |
| Oct 2007 | $11.5M | Series A | – | – | |
| Sep 2007 | $2.03M | Seed | – | – | – |
9 investors in total: 9 institutional.
Investors in Apollo Endo
Apollo Endo has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, UTMB Health and PTV Healthcare Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Global private equity investments are managed by the firm. | athyrium.com | New York, United States | ||
| remeditex.com | ||||
Life Sciences focused VC firm investing in expansion & late stage start-ups in the US | 2003 | ptvhc.com | Austin, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| higbio.com | ||||
Software solutions for mainframe platforms are provided by the company. | 1993 | cpmg.com | Montague, United States | |
Private equity capital is invested in small and mid-sized businesses. | higcapital.com | Miami, United States | ||
University offering multiple courses and degrees across diversified streams | 1891 | utmb.edu | United States | |
Wide range of medical devices | 1979 | bostonscientific.com | Marlborough, United States |
Investor details for Apollo Endo
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Apollo Endo
36 people are tracked at Apollo Endo (11 in leadership, 5 in board & advisors, 20 in team); the tracked headcount is 132.
| Name | Role | Group |
|---|---|---|
Chas McKhann | CEO & President | Leadership |
Keely Scamperle | VP, Reimbursement & Market Access | Leadership |
Tom Neudeck | VP, Research & Development | Leadership |
Felix L. Nieves | Vice President Manufacturing Operations | Leadership |
Jean-Francois Beine | Quality Director | Leadership |
Javier Araya | Global Supply Chain Director | Leadership |
Christopher J. Gostout | Chief Medical Officer | Leadership |
David Hooper | VP, Quality & Regulatory Affairs | Leadership |
Steve Bosrock | VP, Marketing & Medical Education | Leadership |
Kirk Ellis | VP, US Sales | Leadership |
Stuart Barnard | National Sales Director | Leadership |
David C. Pacitti | Director | Board & advisors |
Julie Shimer | Director | Board & advisors |
R. Kent Mcgaughy | Director | Board & advisors |
William D. McClellan Jr. | Director | Board & advisors |
Sharon O’Keefe | Director | Board & advisors |
Alexander Cohen | R&d Engineer II | Team |
Stephen West | Manager, R&d Engineer | Team |
Vlad Mitelberg | Engineering Fellow | Team |
Amanda Green | Sr. Customer Services And Operations Manager | Team |
16 more people are available in the full profile.
Complete people profiles for Apollo Endo
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Apollo Endo
5 dated milestones of Apollo Endo across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Apollo Endo is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $25.0M.
- Exit Acquired by Boston Scientific.
Competitors of Apollo Endo
Apollo Endo has 3 listed competitors in our database, 3 of them funded. They include Allurion, USGI Medical and ReShape.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| allurion.com | 2009 | Wellesley, United States | $174.04M | 252 | Satiety induction through digestable gastric balloon introduced via a swallowed capsule | |
| usgimedical.com | 2001 | San Clemente, United States | $45.95M | Incisionless operating platform for weight loss surgery | ||
| reshapeready.com | 2005 | San Clemente, United States | $90.32M | A dual intra-gastric balloon system is provided for weight loss. |
Detailed competitors of Apollo Endo
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Apollo Endo
Websites that share an audience with Apollo Endo (apolloendo.com).
Websites whose visitors overlap most with Apollo Endo. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arthrocare.com | 99% | View details |
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Apollo Endo (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Apollo Endo
Complete news archive for Apollo Endo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apollo Endo
Apollo Endo was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Apollo Endo is headquartered in Austin, United States. It is registered at Austin, Texas, United States.
Chas McKhann is the CEO of Apollo Endo, as recorded in our data.
Apollo Endo is a funded company, having raised a total of $80.36M across 13 funding rounds to date. The company's 1st funding round was a Seed of $2.03M, raised on Jun 2006.
Apollo Endo has 132 employees.
Annual revenue of Apollo Endo is $76.86M as on Dec 31, 2022.
Apollo Endo was founded in 2005 in Austin, United States, focusing on medical devices within the gastrointestinal sector. Therapeutic solutions for obesity and related disorders are developed, including the Orbera intragastric balloon for portion control and weight management. Additional products encompass the OverStitch Endoscopic Suturing System for advanced endoscopic procedures and the LAP-BAND adjustable gastric banding system. Operations emphasize endoscopic innovations to support clinical applications.
Apollo Endo's top competitors include Allurion, ReShape and USGI Medical.
Apollo Endo offers Endoscopic Sleeve Gastroplasty (ESG), Transoral Outlet Reduction (TORe), and Orbera.
Apollo Endo has 9 investors. Key investors include Boston Scientific, UTMB Health, PTV Healthcare Capital, Athyrium Capital Management, and Remeditex.
Apollo Endo operates through Apollo Endosurgery, Inc..
Yes. Apollo Endo was acquired by Boston Scientific in November 2022.